CCN1/Cyr61 Stimulates Melanogenesis through Integrin α6β1, p38 MAPK, and ERK1/2 Signaling Pathways in Human Epidermal Melanocytes

被引:29
|
作者
Xu, Zhongyi [1 ]
Chen, Li [1 ]
Jiang, Min [1 ]
Wang, Qianqian [1 ]
Zhang, Chengfeng [1 ]
Xiang, Leihong Flora [1 ]
机构
[1] Fudan Univ, Huashan Hosp, Dept Dermatol, 12 Middle Wulumuqi Rd, Shanghai 200040, Peoples R China
关键词
FIBROBLAST-LIKE SYNOVIOCYTES; ACTIVATED PROTEIN-KINASE; MATRICELLULAR PROTEIN; RIEHLS MELANOSIS; GROWTH-FACTOR; HUMAN SKIN; TRANSCRIPTION FACTOR; COLLAGEN HOMEOSTASIS; RHEUMATOID-ARTHRITIS; ENDOTHELIAL-CELLS;
D O I
10.1016/j.jid.2018.02.029
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Fibroblast-derived melanogenic paracrine mediators are known to play a role in melanogenesis. To investigate the effect of CCN1 (also called CYR61 or cysteine-rich 61) on melanogenesis, normal human epidermal melanocytes were treated with recombinant CCN1 protein. Our findings show that CCN1 activates melanogenesis through promoting melanosome maturation and up-regulation of MITF, TRP-1, and tyrosinase via the integrin alpha 6 beta 1, p38 MAPK, and ERK signaling pathways. Furthermore, we found that UVB irradiation stimulates the secretion of CCN1 from normal human dermal fibroblasts, and CCN1 knockdown in fibroblasts attenuates melanogenesis in melanocyte-fibroblast co-culture system. Moreover, using immunohistochemistry and immunofluorescence staining, we discovered that CCN1 is overexpressed in the dermis of both solar lentigines and Riehl's melanosis lesions. These findings suggest that CCN1 is a fibroblast-derived melanogenic paracrine mediator that is secreted under UVB irradiation, and it may play an important role in the development of hyperpigmentation diseases such as Riehl's melanosis.
引用
收藏
页码:1825 / 1833
页数:9
相关论文
共 50 条
  • [22] Pro-angiogenic activities of CYR61 (CCN1) mediated through integrins αvβ3 and α6β1 in human umbilical vein endothelial cells
    Leu, SJ
    Lau, LF
    CIRCULATION, 2002, 106 (19) : 276 - 276
  • [23] Pro-angiogenic activities of CYR61 (CCN1) mediated through integrins αvβ3 and α6β1 in human umbilical vein endothelial cells
    Leu, SJ
    Lam, SCT
    Lau, LF
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (48) : 46248 - 46255
  • [24] IL-1β Upregulates IL-8 Production in Human Müller Cells Through Activation of the p38 MAPK and ERK1/2 Signaling Pathways
    Xiufen Liu
    Fei Ye
    Huabao Xiong
    Danning Hu
    G. Astrid Limb
    Tian Xie
    Liang Peng
    Wei Yang
    Yabin Sun
    Mingming Zhou
    E Song
    David Y. Zhang
    Inflammation, 2014, 37 : 1486 - 1495
  • [25] Fas activates the AP-1 transcription factor via the ERK1/2 and p38 MAPK pathways
    O'Brien, D
    O'Connor, T
    Shanahan, F
    O'Connell, J
    GASTROENTEROLOGY, 2003, 124 (04) : A158 - A158
  • [26] αCGRP Regulates Osteogenic Differentiation of Bone Marrow Mesenchymal Stem Cells Through ERK1/2 and p38 MAPK Signaling Pathways
    Jiang, Yixuan
    Xin, Na
    Xiong, Yi
    Guo, Yanjun
    Yuan, Ying
    Zhang, Qin
    Gong, Ping
    CELL TRANSPLANTATION, 2022, 31
  • [27] Serum amyloid A induces CCL20 secretion in mononuclear cells through MAPK (p38 and ERK1/2) signaling pathways
    Sandri, Silvana
    Hatanaka, Elaine
    Franco, Andressa G.
    Pedrosa, Alziana M. C.
    Monteiro, Hugo P.
    Campa, Ana
    IMMUNOLOGY LETTERS, 2008, 121 (01) : 22 - 26
  • [28] Expression and regulation of the ERK1/2 and p38 MAPK signaling pathways in periodontal tissue remodeling of orthodontic tooth movement
    Jiang, Liping
    Tang, Zhen
    MOLECULAR MEDICINE REPORTS, 2018, 17 (01) : 1499 - 1506
  • [29] Artemisinin Attenuates Isoproterenol-induced Cardiac Hypertrophy via the ERK1/2 and p38 MAPK Signaling Pathways
    Song, Renxing
    Xiong, Chunming
    Bai, Juncai
    Bai, Zhenzhou
    Liu, Wei
    CURRENT MOLECULAR PHARMACOLOGY, 2024, 17
  • [30] Artemisinin Attenuates Isoproterenol-induced Cardiac Hypertrophy via the ERK1/2 and p38 MAPK Signaling Pathways
    Song, Renxing
    Xiong, Chunming
    Bai, Juncai
    Bai, Zhenzhou
    Liu, Wei
    CURRENT MOLECULAR PHARMACOLOGY, 2024, 17